GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

智通财经APP获悉，据知情人士透露，葛兰素史克(GSK.US)正在就收购生物技术公司IDRx进行谈判，对后者的估值可能高达10亿美元。知情人士补充称，谈判仍在进行中，不能保证会达成协议。据悉，IDRx正在开发一种用于胃肠道间质瘤的实验性药物。这笔交易 ...

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...

--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times ...

在生物技术行业的快速变革中，葛兰素史克（GSK）正朝着心仪的收购目标迈出重要一步。最新消息显示，这家制药巨头正在密切洽谈，可能以高达10亿美元的价格收购私有生物技术公司IDRx。此时，IDRx在8月份的一轮融资中已经达到了4.3亿美元的估值，这无疑反映出两者之间巨大潜力与市场看好的前景。

葛兰素史克洽谈收购生物科技公司IDRx，接近就潜在的10亿美元交易达成共识。

【1 月 9 日，葛兰素史克正就收购生物技术公司 IDRx 展开谈判。】IDRx 估值高达 10 亿美元，此交易有望进一步增强 GSK 肿瘤产品组合。IDRx 正在开发一种用于治疗胃肠道间质瘤的实验药物，胃肠道间质瘤是一种出现在消化道的软组织肉瘤。

格隆汇1月9日｜据《金融时报》，葛兰素史克正就收购生物技术公司IDRx进行谈判，IDRx估值高达10亿美元，交易将进一步增强GSK肿瘤产品组合。IDRx正在开发一种治疗胃肠道间质瘤的实验药物，胃肠道间质瘤是一种发生在消化道的软组织肉瘤。

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

GSK and Immunocore hope the TCRs can prove to be in the ‘third generation’ of immuno-oncology drugs, following on from checkpoint inhibitors such as Merck’s Keytruda and BMS’ Opdivo ...